Norton, Larry

Selected publications

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications. 2018 Academic Article GET IT
Times cited: 10
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nature Communications. 2018 Academic Article GET IT
Times cited: 22
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene. Journal of Pathology. 2018 Academic Article GET IT
Times cited: 12
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer. 2018 Academic Article GET IT
Times cited: 3
Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2017 Academic Article GET IT
Times cited: 73
Sleep problems in breast cancer survivors 1–10 years posttreatment. Palliative and Supportive Care. 2017 Academic Article GET IT
Times cited: 8
Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259] (S0960977616301837)(10.1016/j.breast.2016.10.001). Breast. 2017 Article GET IT
Times cited: 3
Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience. Oncologist. 2017 Academic Article GET IT
Times cited: 12
3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017 Review GET IT
Times cited: 104
A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clinical Breast Cancer. 2017 Academic Article GET IT
Times cited: 5
Dealing with the tyranny of certainty in the (medical) digital age. Psycho-Oncology. 2017 Academic Article GET IT
The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology. 2017 Academic Article GET IT
Times cited: 10
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology. 2017 Academic Article GET IT
Times cited: 203
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. Cancer. 2017 Academic Article GET IT
Times cited: 10
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology. 2017 Academic Article GET IT
Times cited: 14
A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 50
A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discovery. 2016 Academic Article GET IT
Times cited: 14
Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. 2016 Academic Article GET IT
Times cited: 39
The genomic landscape of male breast cancers. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 57
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer. 2016 Academic Article GET IT
Times cited: 3
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 23
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Research and Treatment. 2016 Academic Article GET IT
Times cited: 15
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast Cancer Research and Treatment. 2016 Academic Article GET IT
Times cited: 10
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology. 2016 Academic Article GET IT
Times cited: 31
A Pilot Study of Dose-Dense Paclitaxel with Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 2016 Academic Article GET IT
Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: Getting to the heart of the matter. Journal of Clinical Oncology. 2016 Review GET IT
Times cited: 37
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling. 2016 Academic Article GET IT
Times cited: 28
Genome sequencing of multiple primary tumors reveals a novel PALB2 variant. Journal of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 3
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes and Development. 2016 Academic Article GET IT
Times cited: 174
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology. 2016 Academic Article GET IT
Times cited: 42
Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. The Lancet. 2015 Academic Article GET IT
Times cited: 279
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet. 2015 Academic Article GET IT
Times cited: 403
Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology. 2015 Academic Article GET IT
Times cited: 59
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: An exploratory, hypothesis-generating study. Journal of Pathology. 2015 Academic Article GET IT
Times cited: 28
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. Cell Reports. 2015 Academic Article GET IT
Times cited: 8
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biology. 2015 Academic Article GET IT
Times cited: 55
Current management of lesions associated with an increased risk of breast cancer. Nature Reviews Clinical Oncology. 2015 Review GET IT
Times cited: 44
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 49
Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Modern Pathology. 2015 Academic Article GET IT
Times cited: 27
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology. 2015 Review GET IT
Times cited: 73
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Annals of Oncology. 2015 Academic Article GET IT
Times cited: 12
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Molecular Oncology. 2015 Academic Article GET IT
Times cited: 45
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE. 2014 Academic Article GET IT
Times cited: 26
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics. 2014 Academic Article GET IT
Times cited: 107
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Annals of Oncology. 2014 Academic Article GET IT
Times cited: 256
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (alliance). Journal of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 47
Slug promotes survival during metastasis through suppression of puma-mediated apoptosis. Cancer Research. 2014 Academic Article GET IT
Times cited: 21
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene. 2014 Academic Article GET IT
Times cited: 62
Advances in managing breast cancer: A clinical update. F1000Prime Reports. 2014 Review GET IT
Times cited: 10
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biology. 2014 Academic Article GET IT
Times cited: 75
Cancer log-kill revisited. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2014 Review GET IT
Times cited: 5
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Annals of Oncology. 2014 Academic Article GET IT
Times cited: 180
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Conference Paper GET IT
Times cited: 195
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet. 2014 Academic Article GET IT
Times cited: 807
The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute. 2014 Academic Article GET IT
Times cited: 24
TGF-β-Id1 signaling opposes twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Reports. 2013 Academic Article GET IT
Times cited: 109
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Academic Article GET IT
Times cited: 12
Acquired resistance to crizotinib from a mutation in CD74-ROS1. New England Journal of Medicine. 2013 Information Resource GET IT
Times cited: 4
Association between Bone Mineral Density and Incidence of Breast Cancer. PLoS ONE. 2013 Academic Article GET IT
Times cited: 17
Epoetin alfa: To give or not to give. Journal of the National Cancer Institute. 2013 Editorial Article GET IT
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (United States). 2013 Academic Article GET IT
Times cited: 187
P21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis. Oncogene. 2013 Academic Article GET IT
Times cited: 16
Living with metastatic breast cancer: A qualitative analysis of physical, psychological, and social sequelae. Breast Journal. 2013 Academic Article GET IT
Times cited: 32
Spreaders and sponges define metastasis in lung cancer: A markov chain monte carlo mathematical model. Cancer Research. 2013 Academic Article GET IT
Times cited: 43
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clinical Breast Cancer. 2013 Academic Article GET IT
Times cited: 21
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical Cancer Research. 2012 Academic Article GET IT
Times cited: 103
Reply to S. Mahesh. Journal of Clinical Oncology. 2012 Information Resource GET IT
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer. Journal of Mammary Gland Biology and Neoplasia. 2012 Review GET IT
Times cited: 9
Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and leukemia group B 40101. Journal of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 54
DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors. American Journal of Surgical Pathology. 2012 Academic Article GET IT
Times cited: 4
Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?. Journal of Clinical Oncology. 2012 Information Resource GET IT
Times cited: 3
Rare de novo germline copy-number variation in testicular cancer. American Journal of Human Genetics. 2012 Academic Article GET IT
Times cited: 13
Id4 protein is highly expressed in triple-negative breast carcinomas: Possible implications for BRCA1 downregulation. Breast Cancer Research and Treatment. 2012 Academic Article GET IT
Times cited: 25
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012 Academic Article GET IT
Times cited: 481
Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?. Journal of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 33
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Conference Paper GET IT
Times cited: 220
Self-seeding in cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2012 Review GET IT
Times cited: 21
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Research. 2012 Academic Article GET IT
Times cited: 145
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 2012 Academic Article GET IT
Times cited: 14
Randomised trial of expressive writing for distressed metastatic breast cancer patients. Psychology and Health. 2012 Academic Article GET IT
Times cited: 35
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011 Academic Article GET IT
Times cited: 60
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of Oncology. 2011 Academic Article GET IT
Times cited: 40
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): An intergroup trial coordinated by the Eastern Cooperative Oncology Group. Medical Oncology. 2011 Academic Article GET IT
Times cited: 8
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet. 2011 Academic Article GET IT
Times cited: 1584
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 2011 Academic Article GET IT
Times cited: 14
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011 Academic Article GET IT
Times cited: 304
HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research. 2011 Academic Article GET IT
Times cited: 281
p53 expression in node-positive breast cancer patients: Results from the cancer and leukemia group B 9344 trial (159905). Clinical Cancer Research. 2011 Academic Article GET IT
Times cited: 24
Breast cancer tumor size, nodal status, and prognosis: Biology trumps anatomy. Journal of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 28
Tumor self-seeding in breast cancer. Clinical Advances in Hematology and Oncology. 2011 Academic Article GET IT
Times cited: 1
Clinical implications of cancer self-seeding. Nature Reviews Clinical Oncology. 2011 Review GET IT
Times cited: 174
A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical Cancer Research. 2011 Academic Article GET IT
Times cited: 24
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clinical Cancer Research. 2011 Academic Article GET IT
Times cited: 92
Breast cancer methylomes establish an epigenomic foundation for metastasis. Science Translational Medicine. 2011 Academic Article GET IT
Times cited: 180
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes and Development. 2011 Academic Article GET IT
Times cited: 159
Cancer stem cells, EMT, and seeding: A rose is a rose is a rose?. ONCOLOGY. 2011 Article GET IT
Times cited: 3
Cancer stem cells, EMT, and seeding: a rose is a rose is a rose?. ONCOLOGY. 2011 Article GET IT
Times cited: 4
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? results of immunohistochemical analysis and clinical follow-up. American Journal of Surgical Pathology. 2011 Academic Article GET IT
Times cited: 50
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical Breast Cancer. 2011 Academic Article GET IT
Times cited: 79
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Disease. 2010 Academic Article GET IT
Times cited: 19
Capecitabine dosing is not yet optimized for breast cancer. Annals of Oncology. 2010 Information Resource GET IT
Times cited: 1
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. Journal of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 36
Dose-dense chemotherapy for breast cancer: what does the future hold?. Future Oncology. 2010 Review GET IT
Times cited: 8
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical Cancer Research. 2010 Academic Article GET IT
Times cited: 140
Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local-Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082. International Journal of Radiation Oncology Biology Physics. 2010 Academic Article GET IT
Times cited: 11
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 39
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: A pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical Breast Cancer. 2010 Academic Article GET IT
Times cited: 4
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2010 Academic Article GET IT
Times cited: 84
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs. 2010 Review GET IT
Times cited: 349
Tumor Self-Seeding by Circulating Cancer Cells. Cell. 2009 Academic Article GET IT
Times cited: 751
Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. Journal of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 24
Role of anthracyclines in the treatment of early breast cancer. Journal of Clinical Oncology. 2009 Review GET IT
Times cited: 65
The 6q22.33 locus and breast cancer susceptibility. Cancer Epidemiology Biomarkers and Prevention. 2009 Review GET IT
Times cited: 21
Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell. 2009 Academic Article GET IT
Times cited: 412
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Research and Treatment. 2009 Academic Article GET IT
Times cited: 10
Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine. 2009 Academic Article GET IT
Times cited: 363
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: A phase II trial (CALGB 8944). Breast Cancer Research and Treatment. 2009 Academic Article GET IT
Times cited: 12
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical Cancer Research. 2008 Academic Article GET IT
Times cited: 89
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clinical Breast Cancer. 2008 Academic Article GET IT
Times cited: 5
Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 23
Dose-dense chemotherapy with trastuzumab is an appropriate option. Journal of Clinical Oncology. 2008 Information Resource GET IT
Times cited: 1
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: Study 8541 from the cancer and leukemia group B. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 6
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 157
Occult axillary node metastases in breast cancer are prognostically significant: Results in 368 node-negative patients with 20-year follow-up. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 123
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 54
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 457
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Research and Treatment. 2008 Academic Article GET IT
Times cited: 23
Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews. 2008 Academic Article GET IT
Times cited: 10
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology. 2008 Academic Article GET IT
Times cited: 50
Changing indications for surgery in patients with stage IV breast cancer: A current perspective. Cancer. 2008 Academic Article GET IT
Times cited: 15
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 255
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 394
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 43
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics. 2008 Academic Article GET IT
Times cited: 26
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers. Clinical Cancer Research. 2008 Academic Article GET IT
Times cited: 144
Cancer stem cells, self-seeding, and decremented exponential growth: Theoretical and clinical implications. Breast Disease. 2007 Academic Article GET IT
Times cited: 31
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study. Journal of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 284
Tumor dormancy: Separating observations from experimental science. Nature Clinical Practice Oncology. 2007 Article GET IT
Times cited: 1
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007 Review GET IT
Times cited: 1676
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Oncology Practice. 2007 Report GET IT
Times cited: 7
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 22
HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine. 2007 Academic Article GET IT
Times cited: 475
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Annals of Surgical Oncology. 2007 Academic Article GET IT
Times cited: 70
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience. Journal of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 186
Discussion. Clinical Trials. 2007 Comment GET IT
Times cited: 1
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 98
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 67
From the guest editors. Cancer Journal. 2007 Editorial Article GET IT
Keeping faith with trial volunteers: Commentary. Nature. 2007 Academic Article GET IT
Times cited: 16
Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical Cancer Research. 2007 Academic Article GET IT
Times cited: 9
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: Results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment. 2006 Academic Article GET IT
Times cited: 17
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Research. 2006 Academic Article GET IT
Times cited: 248
Role of modeling in pharmacotherapeutics. 2006 Chapter GET IT
Times cited: 1
Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist. 2006 Academic Article GET IT
Times cited: 42
Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clinical Cancer Research. 2006 Academic Article GET IT
Times cited: 61
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment. 2006 Academic Article GET IT
Times cited: 78
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Research and Treatment. 2006 Academic Article GET IT
Times cited: 67
Is cancer a disease of self-seeding?. Nature Medicine. 2006 Academic Article GET IT
Times cited: 244
The Norton - Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nature Clinical Practice Oncology. 2006 Review GET IT
Times cited: 123
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA - Journal of the American Medical Association. 2006 Academic Article GET IT
Times cited: 551
A phase I study of cetuximab in combination with paclitaxel in patients with advanced-stage breast cancer. Clinical Breast Cancer. 2006 Academic Article GET IT
Times cited: 74
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. Journal of Clinical Pathology. 2006 Academic Article GET IT
Times cited: 61
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genetic Epidemiology. 2006 Academic Article GET IT
Times cited: 14
Use of dose-dense chemotherapy in the management of breast cancer. Clinical Advances in Hematology and Oncology. 2006 Review GET IT
Times cited: 7
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. The Lancet. 2005 Article GET IT
Times cited: 3314
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Journal of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 94
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs & aging.. 2005 Academic Article GET IT
Times cited: 22
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. Journal of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 90
Systemic Treatment for Stage I and Stage II Breast Cancer. 2005 Chapter GET IT
Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. American Journal of Surgical Pathology. 2005 Academic Article GET IT
Times cited: 99
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Investigation. 2005 Academic Article GET IT
Times cited: 36
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005 Academic Article GET IT
Times cited: 143
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 2005 Academic Article GET IT
Times cited: 902
Radiation pneumonitis in breast cancer patients treated with taxanes: Does sequential radiation therapy lower the risk?. Breast Journal. 2005 Academic Article GET IT
Times cited: 3
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Journal of the National Cancer Institute. 2005 Academic Article GET IT
Times cited: 69
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Drugs & aging.. 2005 Article GET IT
Times cited: 10
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatment. 2005 Academic Article GET IT
Times cited: 40
Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. Oncologist. 2005 Academic Article GET IT
Times cited: 124
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA - Journal of the American Medical Association. 2005 Academic Article GET IT
Times cited: 296
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 2005 Academic Article GET IT
Times cited: 74
Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Research. 2005 Academic Article GET IT
Times cited: 33
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Annals of Oncology. 2005 Academic Article GET IT
Times cited: 99
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical Breast Cancer. 2005 Academic Article GET IT
Times cited: 53
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer. 2005 Academic Article GET IT
Times cited: 110
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. Journal of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 81
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer. 2004 Academic Article GET IT
Times cited: 32
Current status of dose-dense chemotherapy for breast cancer. Breast Diseases. 2004 Report
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. Journal of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 230
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: A sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Annals of Oncology. 2004 Academic Article GET IT
Times cited: 13
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine. 2004 Academic Article GET IT
Times cited: 696
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: Experience in patients undergoing prophylactic mastectomy. Cancer. 2004 Academic Article GET IT
Times cited: 38
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical Cancer Research. 2004 Academic Article GET IT
Times cited: 26
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical Cancer Research. 2004 Academic Article GET IT
Times cited: 53
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041). Investigational New Drugs. 2004 Academic Article GET IT
Times cited: 6
In reply. Journal of Clinical Oncology. 2003 Article GET IT
Times cited: 1
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. New England Journal of Medicine. 2003 Academic Article GET IT
Times cited: 1546
A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research. 2003 Academic Article GET IT
Times cited: 226
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. Journal of the National Cancer Institute. 2003 Academic Article GET IT
Times cited: 132
Representational oligonucleotide microarray analysis: A high-resolution method to detect genome copy number variation. Genome Research. 2003 Academic Article GET IT
Times cited: 325
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003 Academic Article GET IT
Times cited: 230
Factors influencing treatment patterns of breast cancer patients age 75 and older. Critical Reviews in Oncology and Hematology. 2003 Academic Article GET IT
Times cited: 104
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 52
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. Journal of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 16
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 1178
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 1034
Screening chest imaging studies are not effective in the follow-up of breast cancer patients. The Journal of oncology management : the official journal of the American College of Oncology Administrators. 2003 Academic Article
Times cited: 12
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. Journal of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 25
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: Evidence for involvement of AP-1 and PEA3. Journal of Biological Chemistry. 2002 Academic Article GET IT
Times cited: 293
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2002 Academic Article GET IT
Times cited: 1040
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. Journal of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 72
Focus on breast cancer. Cancer Cell. 2002 Article GET IT
Times cited: 75
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 378
Association of angiogenesis and disease outcome in nodePositive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: A cancer and leukemia group B correlative science study from protocols 8541/8869. Journal of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 21
High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry. Journal of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 56
Existential concerns in late stage cancer. European Journal of Oncology Nursing. 2002 Academic Article GET IT
Times cited: 18
Combined estrogen blockade of the breast with raloxifene and exemestane in postmenopausal women for breast cancer prevention. Breast Cancer Research and Treatment. 2001 Academic Article
Times cited: 3
Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer. Breast Disease. 2001 Academic Article GET IT
Times cited: 1
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Research. 2001 Academic Article GET IT
Times cited: 16
The MORE trial: Multiple outcomes for raloxifene evaluation: Breast cancer as a secondary end point: Implications for prevention. Annals of the New York Academy of Sciences. 2001 Academic Article GET IT
Times cited: 30
Global tobacco control [3]. The Lancet. 2001 Article GET IT
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Research and Treatment. 2001 Academic Article GET IT
Times cited: 156
Editorial: High-dose chemotherapy for breast cancer: "How do you know?". Journal of Clinical Oncology. 2001 Article GET IT
Times cited: 9
Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001 Review GET IT
Times cited: 92
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 523
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCl, in metastatic breast cancer. Journal of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 74
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Breast Cancer Research and Treatment. 2001 Academic Article GET IT
Times cited: 606
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001 Academic Article GET IT
Times cited: 8155
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 165
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 2001 Academic Article GET IT
Times cited: 157
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B study 8662. Clinical Cancer Research. 2001 Academic Article GET IT
Times cited: 92
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-Year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical Cancer Research. 2001 Academic Article GET IT
Times cited: 29
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-Year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical Cancer Research. 2001 Academic Article GET IT
Times cited: 29
Modulation of hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an rb-and schedule-dependent manner. Clinical Cancer Research. 2001 Academic Article GET IT
Times cited: 156
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Research. 2000 Academic Article GET IT
Times cited: 78
An immunotherapeutic approach to treatment of breast cancer: Focus on trastuzumab plus paclitaxel. Cancer Chemotherapy and Pharmacology. 2000 Review GET IT
Times cited: 7
Larry Norton--president-elect of ASCO. American Society of Clinical Oncology. Interviewed by Ezzie Hutchinson. The Lancet Oncology. 2000 Article GET IT
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 159
Systemic 'adjuvant' chemotherapy of primary breast cancer. Current Oncology. 2000 Report
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen- activated protein kinase pathways. Journal of Biological Chemistry. 2000 Academic Article GET IT
Times cited: 290
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clinical Cancer Research. 2000 Academic Article GET IT
Times cited: 168
Association of angiogenesis in lymph node metastases with outcome of breast cancer. Journal of the National Cancer Institute. 2000 Academic Article GET IT
Times cited: 69
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. Journal of Cell Biology. 2000 Academic Article GET IT
Times cited: 676
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 645
Estrogen-receptor status in breast cancer [4] (multiple letters). JAMA - Journal of the American Medical Association. 2000 Article GET IT
Times cited: 1
A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. Psycho-Oncology. 2000 Academic Article GET IT
Times cited: 99
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. Journal of the National Cancer Institute. 1999 Academic Article GET IT
Times cited: 139
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology. 1999 Academic Article GET IT
Times cited: 245
The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA - Journal of the American Medical Association. 1999 Academic Article GET IT
Times cited: 1748
Phase II trial of topotecan in advanced breast cancer. A cancer and leukemia group B study. American Journal of Clinical Oncology: Cancer Clinical Trials. 1999 Academic Article GET IT
Times cited: 17
Adjuvant breast cancer therapy: Current status and future strategies- growth kinetics and the improved drug therapy of breast cancer. Seminars in Oncology. 1999 Review GET IT
Times cited: 41
Kinetic concepts in the systemic drug therapy of breast cancer. Seminars in Oncology. 1999 Review GET IT
Times cited: 37
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. Clinical Cancer Research. 1999 Academic Article GET IT
Times cited: 11
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. Journal of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 48
Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and leukemia group B phase III study 8741. Journal of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 33
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and Leukemia Group B 8642. Journal of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 31
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy. Journal of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 85
Breast cancer advocates in clinical research: A trialist's perspective. Breast Disease. 1998 Comment
Times cited: 3
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. Journal of Clinical Oncology. 1998 Review GET IT
Times cited: 380
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute. 1998 Academic Article GET IT
Times cited: 533
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. Journal of the National Cancer Institute. 1998 Academic Article GET IT
Times cited: 453
Recombinant humanized anti-HER2 antibody (herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Research. 1998 Academic Article GET IT
Times cited: 894
Survival of premenopausal women with breast carcinoma: Effects of menstrual timing of surgery. Cancer. 1998 Academic Article GET IT
Times cited: 7
Tamoxifen for early breast cancer: An overview of the randomised trials. The Lancet. 1998 Academic Article GET IT
Times cited: 3553
BRCA-associated breast cancer in young women. Journal of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 262
BRCA-associated breast cancer: Absence of a characteristic immunophenotype. Cancer Research. 1998 Academic Article GET IT
Times cited: 73
Phase II study of 'dose-dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. Journal of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 47
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Investigation. 1998 Academic Article GET IT
Times cited: 10
The epidermal growth factor receptor modulates the interaction of E- cadherin with the actin cytoskeleton. Journal of Biological Chemistry. 1998 Academic Article GET IT
Times cited: 205
Integration of new therapies into the management of breast cancer. ONCOLOGY. 1998 Comment
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer. Seminars in Oncology. 1997 Academic Article GET IT
Times cited: 17
Pulmonary toxicity of high-dose chemotherapy for breast cancer: A non-invasive approach to diagnosis and treatment. Bone Marrow Transplantation. 1997 Academic Article GET IT
Times cited: 31
Adjuvant drug treatment for resectable breast cancer. Oncologist. 1997 Academic Article GET IT
Times cited: 3
Phase II study of semisynthetic paclitaxel in metastatic breast cancer. European Journal of Cancer. 1997 Academic Article GET IT
Times cited: 12
BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA - Journal of the American Medical Association. 1997 Academic Article GET IT
Times cited: 329
Conceptual basis for advances in the systemic drug therapy of breast cancer. Seminars in Oncology. 1997 Review GET IT
Times cited: 23
Evolving concepts in the systemic drug therapy of breast cancer. Seminars in Oncology. 1997 Review GET IT
Times cited: 133
Innovative approaches to the treatment of advanced breast cancer: Introduction. Seminars in Oncology. 1997 Article GET IT
Times cited: 1
HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. ONCOLOGY. 1997 Review GET IT
Times cited: 141
Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience. ONCOLOGY. 1997 Review GET IT
Times cited: 17
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genetic Testing. 1997 Academic Article GET IT
Times cited: 38
Truth, science, and the oncologist. Annals of the New York Academy of Sciences. 1997 Academic Article GET IT
A stereotactic stand-off. The American Journal of Surgery. 1997 Editorial Article GET IT
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 260
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. Cancer Journal from Scientific American. 1996 Academic Article GET IT
Times cited: 21
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genetics. 1996 Academic Article GET IT
Times cited: 307
Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute. 1996 Academic Article GET IT
Times cited: 587
Adjuvant drug therapy for operable breast cancer. Seminars in Oncology. 1996 Review GET IT
Times cited: 27
Management of advanced breast cancer: Patient needs, challenges and new treatment options: Introduction. Anti-Cancer Drugs. 1996 Academic Article GET IT
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. The Lancet. 1996 Academic Article GET IT
Times cited: 121
Ninety-Six - Hour Paclitaxel Infusion after Progression during Short Taxane Exposure: A Phase II Pharmacokinetic and Pharmacodynamic Study in Metastatic Breast Cancer. Journal of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 151
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Journal of the National Cancer Institute. 1996 Academic Article GET IT
Times cited: 87
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: A cancer and leukemia group B study. Journal of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 47
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics. 1996 Academic Article GET IT
Times cited: 241
Sequential adjuvant therapy: The Memorial Sloan-Kettering Cancer Center experience. Seminars in Oncology. 1996 Academic Article GET IT
Times cited: 27
Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185^HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 1209
Immunophenotype of intraductal carcinoma. Archives of Pathology and Laboratory Medicine. 1996 Academic Article GET IT
Times cited: 79
Implications of a fractal model of neoplasia for the detection of microscopic breast cancer. Breast. 1996 Conference Paper GET IT
Phase II and Pharmacologie Study of Docetaxel as Initial Chemotherapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 142
Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. American Journal of Surgical Pathology. 1995 Academic Article GET IT
Times cited: 20
High-dose chemotherapy of breast cancer. The Canadian journal of oncology. 1995 Review GET IT
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Annals of Oncology. 1995 Review GET IT
Times cited: 19
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Seminars in Oncology. 1995 Academic Article GET IT
Times cited: 23
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seminars in Oncology. 1995 Review GET IT
Times cited: 5
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clinical Cancer Research. 1995 Academic Article GET IT
Times cited: 18
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 202
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: From advanced disease to adjuvant therapy. Seminars in Oncology. 1995 Academic Article GET IT
Times cited: 25
Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. Journal of the National Cancer Institute. 1995 Academic Article GET IT
Times cited: 83
High-dose chemotherapy of breast cancer: Current status and developmental strategies. European Journal of Cancer. 1995 Article GET IT
Times cited: 5
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 56
Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 216
Conditioned Emotional Distress in Women Receiving Chemotherapy for Breast Cancer. Journal of Consulting and Clinical Psychology. 1995 Academic Article GET IT
Times cited: 28
A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene: Implications for Presymptomatic Testing and Screening. JAMA - Journal of the American Medical Association. 1995 Academic Article GET IT
Times cited: 402
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with prosorba columns for treating metastatic breast cancer. Cancer. 1995 Academic Article GET IT
Times cited: 14
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 67
Carboplatin and etoposide in metastatic breast cancer [1]. Annals of Oncology. 1995 Article GET IT
Times cited: 2
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 70
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer. 1995 Academic Article GET IT
Times cited: 110
Refining the origins of breast cancer. Nature Medicine. 1995 Article GET IT
Times cited: 1
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer. Annals of Oncology. 1995 Academic Article GET IT
Times cited: 27
p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. Journal of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 127
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplantation. 1994 Academic Article GET IT
Times cited: 21
Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood. 1994 Academic Article GET IT
Times cited: 74
Salvage chemotherapy of breast cancer. Seminars in Oncology. 1994 Review GET IT
Times cited: 23
Symptom prevalence, characteristics and distress in a cancer population. Quality of Life Research. 1994 Academic Article GET IT
Times cited: 472
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New England Journal of Medicine. 1994 Academic Article GET IT
Times cited: 611
Discussion. Seminars in Oncology. 1994 Conference Paper
High-intensity chemotherapy with peripheral blood progenitor cell support. Seminars in Oncology. 1994 Review GET IT
Times cited: 13
Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. American Journal of Surgical Pathology. 1994 Academic Article GET IT
Times cited: 35
Kinetic basis of breast cancer. Minerva Medica. 1994 Review GET IT
Times cited: 2
Re: (we may be lost, but we're sure makin' good time). Cancer Investigation. 1994 Article GET IT
Sequential high-dose chemotherapy in solid tumours with PBC support. Bone Marrow Transplantation. 1994 Article GET IT
Simultaneous Dose Escalation and Schedule Intensification of Carboplatin-based Chemotherapy Using Peripheral Blood Progenitor Cells and Filgrastim: A Phase I Trial. Cancer Research. 1994 Academic Article GET IT
Times cited: 21
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. Oncology (Switzerland). 1994 Academic Article GET IT
Times cited: 3
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. International Journal of Clinical and Laboratory Research. 1994 Article GET IT
Times cited: 68
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. European Journal of Cancer. 1994 Academic Article GET IT
Times cited: 987
Systemic adjuvant therapy for breast cancer. Current Opinion in Oncology. 1993 Review GET IT
Times cited: 4
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. Journal of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 69
Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. Journal of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 226
High-intensity chemotherapy with hematopoietic support in breast cancer. Annals of the New York Academy of Sciences. 1993 Review GET IT
Times cited: 5
Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. Journal of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 64
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report. Annals of the New York Academy of Sciences. 1993 Academic Article GET IT
Times cited: 2
Use of ultrasound to guide radiation boost planning following lumpectomy for carcinoma of the breast. International Journal of Radiation Oncology Biology Physics. 1993 Academic Article GET IT
Times cited: 31
Kinetic concepts in the treatment of breast cancer. Annals of the New York Academy of Sciences. 1993 Review GET IT
Times cited: 12
Preliminary experience with paclitaxel (TAXOL®) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Seminars in Oncology. 1993 Academic Article GET IT
Times cited: 43
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 392
Phase I trial of granulocyte - macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: A cancer and leukemia group B study. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 39
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Investigation. 1993 Academic Article GET IT
Times cited: 9
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial. Cancer. 1993 Academic Article GET IT
Times cited: 50
Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy. Behaviour Research and Therapy. 1993 Academic Article GET IT
Times cited: 28
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 513
Kinetic concepts in the treatment of breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1993 Review GET IT
Times cited: 5
Milk fistula: A complication after core breast biopsy. American Journal of Roentgenology. 1993 Academic Article GET IT
Times cited: 72
Modeling the Development of Metastases from Primary and Locally Recurrent Tumors: Comparison with a Clinical Data Base for Prostatic Cancer. Cancer Research. 1993 Academic Article GET IT
Times cited: 52
Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer. 1993 Academic Article GET IT
Times cited: 11
Timing of radiotherapy in the treatment of early-stage breast cancer [1]. Journal of Clinical Oncology. 1993 Article GET IT
Times cited: 12
Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells [1]. Journal of the National Cancer Institute. 1992 Article GET IT
Times cited: 32
An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosomatic Medicine. 1992 Academic Article GET IT
Times cited: 47
Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Seminars in Surgical Oncology. 1992 Academic Article GET IT
Times cited: 38
Evolving concepts in the adjuvant systemic therapy of operable breast cancer. Cancer treatment and research. 1992 Review GET IT
Precholecystectomy endoscopic cholangiography and stone removal is not superior to cholecystectomy, cholangiography, and common duct exploration. The American Journal of Surgery. 1992 Academic Article GET IT
Times cited: 135
The Scientific Data Audit System of the Cancer and Leukemia Group B (CALGB). Accountability in Research. 1992 Academic Article GET IT
Times cited: 1
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: A cancer and leukemia group B study. Journal of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 64
Minimal access surgery for gastroesophageal reflux: laparoscopic placement of the Angelchik prosthesis in pigs. Surgical Endoscopy. 1991 Academic Article GET IT
Times cited: 19
A Prospective Study of Incisional Time, Blood Loss, Pain, and Healing with Carbon Dioxide Laser, Scalpel, and Electrosurgery. Archives of Surgery. 1991 Academic Article GET IT
Times cited: 40
Adjuvant systemic therapy for early breast cancer. Seminars in Surgical Oncology. 1991 Academic Article GET IT
Times cited: 2
Chemotherapy of metastatic merkel cell cancer. Cancer Investigation. 1991 Academic Article GET IT
Times cited: 39
Decision for surgical management of perforation following endoscopic sphincterotomy. American Surgeon. 1991 Academic Article GET IT
Times cited: 44
Metastatic breast cancer - Length and quality of life. New England Journal of Medicine. 1991 Article GET IT
Times cited: 24
Potential innovations in scheduling of cancer chemotherapy. Important advances in oncology. 1991 Review GET IT
Times cited: 47
The cost effectiveness of breast biopsy techniques. Problems in General Surgery. 1991 Report
Times cited: 1
The next step. Surgery. 1991 Editorial Article GET IT
Times cited: 3
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study. Medical and Pediatric Oncology. 1991 Academic Article GET IT
Times cited: 12
Biology of residual breast cancer after therapy: a kinetic interpretation. Progress in clinical and biological research. 1990 Review GET IT
Times cited: 4
Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases - A Cancer and Leukemia Group B report. Investigational New Drugs. 1990 Academic Article GET IT
Times cited: 5
A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non‐Hodgkin's lymphomas cancer and leukemia group B study 7851. Cancer. 1990 Academic Article GET IT
Times cited: 19
Chemotherapy for large cell lymphoma: A status update. Seminars in Oncology. 1990 Review GET IT
Times cited: 34
Endoscopic versus operative gastrostomy: Final results of a prospective randomized trial. Gastrointestinal Endoscopy. 1990 Academic Article GET IT
Times cited: 188
Insulin Protects Against Muscle Proteolysis Induced by Septic Plasma. Archives of Surgery. 1990 Academic Article GET IT
Phase II study of moplace chemotherapy for patients with previously treated Hodgkin's disease: A calgb study. Medical and Pediatric Oncology. 1990 Academic Article GET IT
Times cited: 15
Resident Training. Archives of Surgery. 1990 Article GET IT
The surgical management of atypical mycobacterial soft-tissue infections. Surgery. 1990 Academic Article GET IT
Times cited: 46
Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukemia group B study. The American Journal of Medicine. 1989 Academic Article GET IT
Times cited: 80
Reply. Cancer Research. 1989 Information Resource
Times cited: 3
A good offense. Surgery. 1989 Editorial Article GET IT
Times cited: 1
Effect of cancer plasma on skeletal muscle metabolism. Journal of Surgical Research. 1989 Academic Article GET IT
Times cited: 4
Endoscopic Cholangiography and Stone Removal Prior to Cholecystectomy: A More Cost-effective Approach Than Operative Duct Exploration?. Archives of Surgery. 1989 Academic Article GET IT
Times cited: 49
A Gompertzian Model of Human Breast Cancer Growth. Cancer Research. 1988 Academic Article GET IT
Times cited: 465
Cancer plasma effects on skeletal muscle metabolism. Current Surgery. 1988 Academic Article GET IT
Accuracy and Cost of Needle Localization Breast Biopsy. Archives of Surgery. 1988 Academic Article GET IT
Times cited: 55
Chemoprevention breast cancer workshop, november 20, 1987 panel discussions. Cancer Investigation. 1988 Academic Article GET IT
Implications of growth kinetic concepts for cancer chemoprevention. Cancer Investigation. 1988 Academic Article GET IT
Needle localization breast biopsy: Accuracy versus cost. The American Journal of Surgery. 1988 Academic Article GET IT
Times cited: 19
Operative versus endoscopic gastrostomy. Preliminary results of a prospective randomized trial. The American Journal of Surgery. 1988 Academic Article GET IT
Times cited: 31
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (Adriamycin), vincristine and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: Preliminary report of cancer and leukemia group B study 7851. NCI Monographs. 1987 Academic Article GET IT
Times cited: 10
A phase I-II study of intensive-dose adriamycin for advanced breast cancer. Journal of Clinical Oncology. 1987 Academic Article GET IT
Times cited: 110
Treatment of acute necrotizing hemorrhagic pancreatitis. Digestive Surgery. 1987 Academic Article
Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. American Journal of Clinical Oncology: Cancer Clinical Trials. 1986 Academic Article GET IT
Times cited: 10
Duodenojejunostomy for the pancreaticobiliary complications of duodenal diverticulum. Annals of Surgery. 1986 Article GET IT
Times cited: 1
The Norton-Simon hypothesis revisited. Cancer Treatment Reports. 1986 Academic Article GET IT
Times cited: 362
Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: Cancer and leukemia group B trial 8171. Cancer Treatment Reports. 1985 Academic Article GET IT
Times cited: 8
Does drainage of intraabdominal pus reverse multiple organ failure?. The American Journal of Surgery. 1985 Academic Article GET IT
Times cited: 78
Enhancement of differentiation of HL-60 cells by pulsatile electromagnetically induced currents (PEMIC). Proceedings of the American Association for Cancer Research. 1985 Academic Article
Implications of kinetic heterogeneity in clinical oncology. Seminars in Oncology. 1985 Review GET IT
Times cited: 75
Pharmacokinetics of Vindesine Given as an Intravenous Bolus and 24-Hour Infusion in Humans. Cancer Research. 1985 Academic Article GET IT
Times cited: 13
Thoughts on the surgical staging of lymphomas. Mount Sinai Journal of Medicine. 1985 Academic Article GET IT
Tumor growth kinetics. Mount Sinai Journal of Medicine. 1985 Academic Article GET IT
Times cited: 2
Experimental and Clinical Activity of Mitomycin C and cis-Diamminedichloroplatinum in Malignant Mesothelioma. Cancer Research. 1984 Academic Article GET IT
Times cited: 47
Accuracy of aspiration cytology in detecting breast cancer. Surgery. 1984 Academic Article GET IT
Times cited: 38
Will the general surgeon become extinct?. World Journal of Surgery. 1983 Information Resource GET IT
Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Medical and Pediatric Oncology. 1983 Academic Article GET IT
Times cited: 54
Intensive six-week courses of combination chemotherapy in stage IV breast carcinoma. Proceedings of the American Society of Clinical Oncology. 1982 Academic Article
Times cited: 1
Utility of thyroid aspiration biopsy. Surgery. 1982 Academic Article GET IT
Times cited: 18
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Annals of Internal Medicine. 1982 Academic Article GET IT
Times cited: 268
A lump in the breast: assessment and options for local treatment. Arizona Medicine. 1982 Academic Article GET IT
Needle aspiration biopsy of thyroid nodules. Arizona Medicine. 1981 Academic Article GET IT
Non-monotonic dose-response to chemotherapy of murine B-16 melanoma (MM). Proceedings of the American Association for Cancer Research. 1981 Academic Article
Times cited: 2
Nodular histiocytic lymphoma: An aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood. 1980 Academic Article GET IT
Times cited: 39
Outcome of Operations for Upper Gastrointestinal Tract Bleeding: An Update. Archives of Surgery. 1980 Academic Article GET IT
Times cited: 9
Selective Intra-arterial Vasopressin Infusion for Upper Gastrointestinal Tract Hemorrhage: A Controlled Trial. Archives of Surgery. 1980 Academic Article GET IT
Times cited: 58
Small bowel neomucosa. Journal of Surgical Research. 1980 Academic Article GET IT
Times cited: 37
Caroli's disease: a surgical challenge. American Surgeon. 1979 Academic Article GET IT
Times cited: 3
Invited commentary. World Journal of Surgery. 1979 Academic Article GET IT
Accuracy of techniques to detect intraperitoneal abscess. Obstetrical and Gynecological Survey. 1979 Academic Article GET IT
Massive cecal dilation: Pseudoobstruction versus cecal volvulus?. The American Journal of Surgery. 1979 Academic Article GET IT
Times cited: 24
Treatment of advanced breast cancer with a novel cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F), vincristine (V) and prednisone (P) regimen. Proceedings of the American Association for Cancer Research. 1979 Academic Article
Accuracy of techniques to detect intraperitoneal abscess. Surgery. 1978 Academic Article GET IT
Times cited: 24
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo. Cancer Treatment Reports. 1978 Academic Article GET IT
Times cited: 14
Gastric ulcers following vagotomy in piglets. World Journal of Surgery. 1978 Academic Article GET IT
Times cited: 1
A new method for screening anti-cancer agents on solid tumors. Proceedings of the American Association for Cancer Research. 1978 Academic Article
Condyloma: A New Epidemic. Archives of Surgery. 1978 Academic Article GET IT
Times cited: 6
Depression of Cell-Mediated Immunity in Diabetes. Archives of Surgery. 1978 Academic Article GET IT
Times cited: 37
Immunologic studies of canine lymphosarcoma: Mixed leukocyte reactivity following chemotherapy. Clinical Immunology and Immunopathology. 1978 Academic Article GET IT
Times cited: 3
Preventing bile reflux by intussusception gastroduodenostomy. Journal of Surgical Research. 1978 Academic Article GET IT
Times cited: 1
Statistical considerations in determination of ventricular volume from echocardiographic and angiographic data. American Journal of Cardiology. 1978 Article GET IT
The continuing challenge of duodenal injuries. Journal of Trauma - Injury, Infection and Critical Care. 1978 Academic Article GET IT
Times cited: 35
The treatment of combination chemotherapy‐resistant Hodgkin disease with single‐agent vinblastine. American Journal of Hematology. 1978 Academic Article GET IT
Times cited: 6
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treatment Reports. 1977 Academic Article GET IT
Times cited: 127
Hepatic support with hepatocyte suspensions in a permeable membrane dialyzer. Surgery. 1977 Academic Article GET IT
Times cited: 47
Migration of transfused granulocytes in leukopenic dogs. Blood. 1977 Academic Article GET IT
Times cited: 18
Multiple organ failure. Surgery Gynecology and Obstetrics. 1977 Academic Article GET IT
Times cited: 244
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treatment Reports. 1977 Academic Article GET IT
Times cited: 406
Clinical indications and accuracy of gray scale ultrasonography in the patient with suspected biliary tract disease. The American Journal of Surgery. 1977 Academic Article GET IT
Times cited: 18
Effect of prior radiotherapy on tolerance and response to chemotherapy in non‐hodgkin's lymphoma. American Journal of Hematology. 1977 Academic Article GET IT
Times cited: 4
Growth curve of an experimental solid tumor following radiotherapy. Journal of the National Cancer Institute. 1977 Academic Article GET IT
Times cited: 92
Depressed cellular immunity in diabetics. Surgical Forum. 1976 Academic Article GET IT
Times cited: 3
Hepatocyte perfusion within a centrifuge. Surgery Gynecology and Obstetrics. 1976 Academic Article GET IT
Times cited: 27
Predicting the course of Gompertzian growth. Nature. 1976 Academic Article GET IT
Times cited: 211
Community experience with small bowel bypass for morbid obesity. The American Journal of Surgery. 1976 Academic Article GET IT
Times cited: 4
Morbidity of colostomy closure. The American Journal of Surgery. 1976 Academic Article GET IT
Times cited: 58
Current management of upper gastrointestinal bleeding. Annals of Surgery. 1975 Academic Article GET IT
Times cited: 18
Growing small bowel mucosa: an experimental approach to the short bowel syndrome. Surgical Forum. 1975 Academic Article GET IT
Times cited: 7
Accuracy of Ultrasound in Diagnosing Abdominal Masses. Archives of Surgery. 1975 Academic Article GET IT
Times cited: 24
Cholecystectomy with and without surgical drainage. The American Journal of Surgery. 1975 Academic Article GET IT
Times cited: 31
Gastric mucosal ischemia in experimental stress ulcer. Journal of Surgical Research. 1975 Academic Article GET IT
Times cited: 22
Incidental appendicectomy with laparotomy for trauma. British Journal of Surgery. 1975 Academic Article GET IT
Times cited: 8
Liver failure in the postoperative patient: The role of sepsis and immunologic deficiency. Surgery. 1975 Academic Article GET IT
Times cited: 49
Massive right upper quadrant intra-abdominal injury requiring pancreaticoduodenectomy and partial hepatectomy. Journal of Trauma - Injury, Infection and Critical Care. 1975 Academic Article GET IT
Times cited: 12
Operative Choice and Technique Following Pancreatic Injury. Archives of Surgery. 1975 Academic Article GET IT
Times cited: 37
Replacement of portal vein during pancreatectomy for carcinoma. Surgery. 1975 Academic Article GET IT
Times cited: 60
Liver injuries: Controversies about their treatment. Evaluation of 300 cases. Prensa Medica Argentina. 1974 Academic Article
Times cited: 1
Pharmacological protection against swine stress ulcer. Gastroenterology. 1974 Academic Article GET IT
Times cited: 18
The effects of brain stem compression on the heart. Surgical Neurology. 1974 Academic Article GET IT
Times cited: 3
Management of pseudo-obstruction of the colon. Surgery Gynecology and Obstetrics. 1974 Academic Article GET IT
Times cited: 40
Resident-prepared audio-visual programs for teaching operative technique. Journal of Surgical Research. 1974 Academic Article GET IT
Times cited: 1
Gastric mucosal blood flow measurement. Journal of Surgical Research. 1974 Academic Article GET IT
Times cited: 3
Near total pancreatectomy for hemorrhagic pancreatitis. The American Journal of Surgery. 1974 Academic Article GET IT
Times cited: 42
Bile and stress ulcer. Surgery. 1973 Academic Article
Injuries associated with renal trauma. Journal of Urology. 1973 Academic Article GET IT
Times cited: 11
Liver failure in the surgical patient. BULL.SOC.INT.CHIR.. 1973 Academic Article GET IT
Reply. Surgery. 1973 Information Resource
Growth, inhibition and suppression of mouse melanoma on the isolated perfused pig spleen. Review of surgery. 1973 Academic Article GET IT
Bile reflux in experimental stress ulcer. Surgery. 1973 Academic Article GET IT
Times cited: 24
Gastric Blood Flow in Endotoxin-Induced Stress Ulcer. Archives of Surgery. 1973 Academic Article GET IT
Times cited: 48
Training foreign academicians in U.S. medical schools. Journal of Surgical Research. 1973 Academic Article GET IT
Cardiovascular effects of increased intracranial pressure. Surgical Forum. 1972 Academic Article GET IT
A swine stress ulcer model. Annals of Surgery. 1972 Academic Article GET IT
Times cited: 18
A new venous prosthesis. Surgery. 1972 Academic Article GET IT
Times cited: 196
Gastric secretory response to pressure on vagal nuclei. The American Journal of Surgery. 1972 Academic Article GET IT
Times cited: 12
Immunologic response to melanoma of sensitized perfused bone and spleen. Journal of Surgical Oncology. 1972 Academic Article GET IT
Metabolic and immunologic studies of perfused bone in vitro. Journal of Bone and Joint Surgery - American Volume. 1972 Academic Article GET IT
Times cited: 1
Cyclic adenosine 3', monophosphate 5', thyrocalcitonin, parathyroid hormone, and the isolated perfused bone. Surgical Forum. 1971 Academic Article GET IT
Growth, inhibition and suppression of mouse melanoma on isolated perfused pig spleen. Surgical Forum. 1971 Academic Article GET IT
Times cited: 1
Prolonged experimental bone perfusion. Surgical Forum. 1970 Academic Article GET IT
Times cited: 1
Gastric Secretory Response to Head Injury. Archives of Surgery. 1970 Academic Article GET IT
Times cited: 44
THE ROLE OF SURGERY IN CARCINOMA OF THE UTERINE CERVIX. The Journal of the Kentucky Medical Association. 1964 Academic Article GET IT
Long-Term Comparison Of Vein Patch With Direct Suture: Technique of Anastomosis of Small Arteries. Archives of Surgery. 1964 Academic Article GET IT
Times cited: 11
Coronary Artery Patch Graft: Experiment with Cardiopulmonary Bypass and Hypothermia. Archives of Surgery. 1963 Academic Article GET IT
Times cited: 1

VIVO Weill Cornell Medical College

Larry Norton Professor of Medicine

Publications

Selected publications

Background

Education and Training

Phone

Publications

Selected publications

Background

Education and Training